CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Professor Erling Tronvik MD, PhD

Editorial Board

Assistant Professor and Consultant Neurologist

Norwegian Advisory Unit on Headaches, St. Olavs Hospital,
Department of Neuromedicine and Movement Science,
NTNU Norwegian University of Science and Technology, Norway

Erling Tronvik is currently working as a senior consultant at the Department of Neurology, St.Olavs Hospital, Trondheim Norway and the Norwegian Advisory Unit on Headaches. In addition he has a position as associate professor at the Department of Neuromedicine and Movement Science, NTNU; Norwegian University of Science and Technology where he is responsible for the training of medical students in neurology. His main interest in the headache field is prophylactic treatment of migraine and cluster headache, as this is an area where, in his opinion, too little progress has been made in previous years. The Norwegian Advisory Unit on Headaches is involved in a broad spectrum of headache research from epidemiological studies, neurophysiological trials, genetic research and clinical headache trials. Currently, his main focus is interventional projects, using image-guided techniques to target neural structures in the head/neck area in headache conditions.

« Back to Editorial Board

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |